and Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM
Common side effects include nausea, vomiting, and constipation
23 Dedicated renal outcome trials of tirzepatide are warranted
Consistent with these effects, GLP-1 RAs have been associated with substantial weight loss in clinical trials, leading to FDA approval of two of these agents liraglutide and semaglutide for chronic weight management in adults with obesity or with overweight and at least one weight-related comorbidity
If you only remember one thing: Always consult with an experienced personal injury attorney as soon as possible after a suspected injury from GLP-1 drugs
doi: 10.1002/ca.21011 28 GutierrezRSimonSA